Background: Remifentanil is associated with subjective dysphagia and an objective
| INTRODUCTION
Remifentanil is an ultra-short-acting mu-opioid receptor (MOR) agonist, used during anesthesia for its centrally depressing and antinociceptive effects. Many individuals, including healthy volunteers, complain of dysphagia during administration of remifentanil. 1, 2 Recent descriptions of the effects of remifentanil and other MOR agonists on swallowing function have revealed attenuated oropharyngeal 3, 4 and laryngeal 5 sensory function, increased pulmonary aspiration, 2 decreased distal esophageal latency 6, 7 , and decreased esophagogastric junction (EGJ) relaxation. [6] [7] [8] [9] [10] [11] Esophageal pressure
Abbreviations: DCI, distal contractile integral; DCL, distension-contraction latency; EGJ, esophagogastric junction; IRP4, 4 second integrated relaxation pressure; LES, lower esophageal sphincter; MOR, Mu-opioid receptor.
topography (EPT) revealed a shortened distal latency and increased distal intrabolus pressure during remifentanil administration. 7 The integrated relaxation pressure in 4 seconds (IRP4), a measure of EGJ relaxation, increased but remained well within physiological limits.
Patients on chronic opioids frequently have evidence of EGJ obstruction and likely related distal esophageal hypercontractility. 6 The mechanisms of the observed esophageal changes and the origin of the sensation of dysphagia are incompletely understood.
The use of computer-based analyses of high-resolution impedance manometry recordings enables us to relate pressure-flow phenomena to their functional consequences, including the completeness of impedance-based bolus passage and bolus-based esophageal distension and related pressures. 12 Separate evaluation can be undertaken of the proximal and distal esophagus, as well as the EGJ with the intention to relate pressure-flow phenomena to physiology, pathophysiology, and symptoms. 12, 13 Esophageal pressure-flow analysis has not been performed during administration of remifentanil and offers the opportunity to enhance our understanding of changes in esophageal physiology induced by opioids.
Bolus flow phenomena are important in determining successful bolus passage through the hollow organs of the gastrointestinal tract such as the tubular esophagus. This is of particular interest as the human esophagus consists of proximal striated and distal smooth muscle, with potentially different effects in relation to such physiological events as bolus-based distension. Our group has previously described the concept of the "neuromechanical loop" in which bolus distension causes orad contraction and aboral relaxation of circular muscle with the subsequent movement of content then generating the new mechanical stimulus that activates intramuscular tension receptors reinitiating the sequence. 14,15 Page and colleagues described attenuated responses in mucosal and tension receptors following MOR agonism in the ferret esophagus, meaning a greater stimulus is needed to invoke the same neuro-mechanical response. 16 It can thus be hypothesized that the increased intrabolus pressure observed during remifentanil exposure represents retained bolus due to decreased EGJ relaxation. 7 In this study, we sought to further characterize the effect of MOR on esophageal segment physiology using state-ofthe-art methods. We therefore conducted novel pressure-impedance analyses on manometric recordings from healthy volunteers before and during remifentanil administration. The aim of this study was to determine how mechanisms of compartmentalized bolus transport and esophageal emptying are affected by exposure to remifentanil.
| MATERIALS AND METHODS

| Subjects
Data from 11 healthy young participants (mean age 23 ± 3 years, 7 male), collected at the Department of Anaesthesiology, University
Hospital in Örebro, Sweden, were analyzed. All participants were previously enrolled in a double-blind, randomized, placebo-controlled, cross-over study of opioid drugs on pharyngeal swallowing 3 , and all gave informed consent. The protocol of this study was reviewed and approved by the Central Ethics Review Board in Uppsala, Sweden.
None of the participants smoked, reported any current or past symptoms of dysphagia or upper gastrointestinal diseases, or took any medications that could affect pharyngeal or esophageal function.
Exclusion criteria for this study included potential pregnancy, current breastfeeding, or previous participation in a medical study.
| Intervention
Intravenous target-controlled infusion was used to administer remifentanil with an effect-site concentration of 3 ng/mL (Minto Model, Alaris PK syringe pump, Alaris Medical Nordic AB, Sollentuna, Sweden). The infusion pump uses a 3-compartment model described by Minto 17, 18 (variates are lean body mass and age) to calculate dose administration.
The system delivers a brief, rapid infusion to reach the targeted effect size concentration without overshoot, followed by a series of decreasing infusion rates to maintain the targeted concentration.
| High-resolution impedance manometry
Manometry and impedance data were recorded using a 4. 
Key Points
• Mu-opioid receptor agonism induces the symptom dysphagia, as well as changes in esophageal motility and lower esophageal sphincter relaxation. We assessed the functional effects of such changes.
• MOR agonism has differential effects in the proximal and distal esophagus, however trans-sphincteric bolus flow is maintained through increased intrabolus pressure.
• Remifentanil leads to reduced proximal skeletal muscle contractility and a loss of inhibition in the distal (smooth muscle) esophagus, with resulting shortened distal latency, increased contractile vigor and numerically increased IRP.
| EGJ metrics
Bolus flow through the EGJ was determined as described by Lin et al. 19 In brief, the method consists of creating a virtual e-sleeve at the EGJ to simultaneously measure pressure and impedance data in determined for the EGJ in the same way as that for the esophagus described below. The EGJ nadir pressure was also measured as a discreet value.
| Pressure-flow analysis
Swallows were analyzed using purpose-designed software (based Five space-time landmarks were determined on the plot as follows (see also Figure 1 ):
Swallow onset determined by the onset of upper esophageal
sphincter (UOS) relaxation.
2.
The temporospacial position of the peak esophageal pressure at the orad margin of the proximal esophagus. 
| Esophageal pressure-flow variables
Swallow function variables during PFA were determined for the whole esophagus and esophagus proximal to, but excluding the transition zone (proximal esophagus) and esophagus from the transition zone to the proximal margin of the LES high-pressure zone (distal esophagus). As it has been determined that nadir impedance F I G U R E 1 Esophageal pressure topography (A), esophageal contour plot (B) and peak distension and contraction used during pressure-flow analysis (C). Five user-defined landmarks are used for analysis, namely (1) swallow onset, (2) orad onset of peak pressure wave -both time and space, (3) midpoint of transition zone, (4) proximal margin of the EGJ high-pressure zone, and (5) for the complete distal esophagus as the mean value of the ratio of nadir impedance to the impedance at peak pressure. A higher ratio implies relatively more bolus retention as the drop in impedance is determined by the presence of bolus.
| Esophageal pressure topography
Esophageal Pressure Topography was determined by Chicago Classification Criteria. 23 Swallow onset was defined as the onset of relaxation in the upper esophageal sphincter (UES) high-pressure zone. The integrated relaxation pressure in 4 seconds (IRP4) was determined as the lowest contiguous or non-contiguous pressure in the lower esophageal sphincter (LES) high-pressure zone in the 10 seconds following swallow onset. IRP4 is referenced to intragastric pressure.
Contraction deceleration point (CDP) was determined as the inflection in peristaltic velocity within the distal esophagus 2-3 cm from the EGJ.
This inflexion is indicative of the formation of the phrenic ampulla associated with distal esophageal bolus clearance. The time from swallow onset to the CDP was termed the distal latency (DL), measured in seconds. Peristaltic velocity was determined by drawing a line parallel to the 30 mm Hg isocontour starting at the CDP and extending proximally.
| Statistical analysis
Bonferroni-adjusted paired t tests were used to compare outcome variables measured before and during exposure to remifentanil. These are presented here as mean ± standard error (t-statistic) with a Pvalue < .05 indicating statistical significance.
| RESULTS
The total cumulative dose of remifentanil administered in our volunteers ranged from 346 to 487 μg.
Two of the subjects reported a subjective sensation of dysphagia during the infusion, while some other subjects reported nausea. Most of the subjects described feeling sedated. All the side-effects rapidly disappeared on stopping the infusion. Tables 1 and 2 .
| Bolus flow through the EGJ
Effects on bolus flow as measured through bolus flow time and bolus presence time are pictured in Figures 3 and 4 and Table 1 . Both BFT and BPT
were markedly reduced during administration of Remifentanil (Table 1) .
F I G U R E 3 Distal latency (A) and distension-contraction latency for the proximal (B) and distal (C) esophagus during remifentanil F I G U R E 4 EGJ bolus flow in healthy volunteers following remifentanil. Reduced bolus presence and flow times are observed during remifentanil using the methodology described by Lin et al 19 
F I G U R E 5
Overlay of esophageal body topography and distension timing. From these data it is apparent that timing and velocity remains constant in the proximal esophagus with reduced distension-contraction latency and increased velocity in the distal esophagus during remifentanil 
| Pressure-flow analysis
Effects of Remifentanil on pressure-flow analysis are shown in Table 1 . Peristalsis remained intact and of an equivalent vigor in the distal esophagus. There were reduced peak pressures in the proximal (striated) esophagus. There was evidence of increased intrabolus distension pressures throughout the esophagus. Additionally, IBP slope increased significantly in the distal esophagus only from 1.1 ± 0.6 mm Hg/s pre to 3.9 ± 0.9 mm Hg/s during remifentanil exposure (P = .03). Esophageal luminal cross-sectional area, inferred by distension impedance, remained unchanged throughout the es-
ophagus. Distension-contraction latency time (DCL) was significantly
shorter during remifentanil exposure in the distal esophagus only ( Figures 3B and 3C, 5 ).
| Esophageal pressure topography
Effects of Remifentanil on EPT metrics are shown in Table 2 . No subjects fulfilled Chicago classification diagnosis for motor abnormalities prior to commencing the remifentanil infusion.
The most marked effect of Remifentanil exposure was a reduced distal latency (Table 2 ; Figure 3A ). In addition, there was a strong trend approaching significance for increased peristaltic velocity in the smooth muscle esophagus, likely associated with the shortening of distal latency. 24 There were no statistically significant differences in peristaltic vigor as measured through DCI. EGJ relaxation pressures as measured by IRP4 were not significantly different during remifentanil exposure overall, even though the IRP4 was increased numerically in 6 of the subjects.
| DISCUSSION
In this study, we evaluated the pharmacodynamic effects of the mu- 
| Remifentanil effects on proximal esophageal motility
The central nervous system, via brainstem-based central pattern generators of swallowing, initiates and controls proximal striated muscle peristalsis via sequential activation of motor neurone pools within the nucleus ambiguus. 25 Central sensory relay occurs in the nucleus tractus solitarius (NTS), 26 and motor outputs are modulated in response to sensory input for different bolus characteristics. 27, 28 In our study, remifentanil exposure reduced proximal esophageal contractility, suggesting either central effects leading to attenuated motor neurone activation or, alternatively, peripheral effects at the striated neuromuscular junction. Central modulation may occur at the level of the NTS as it has been shown to contain MOR. 29, 30 However, one might expect that besides T A B L E 2 Esophageal pressure topography metrics prior to (Baseline) and 30 min during administration of remifentanil (remifentanil)
| Remifentanil effects on distal esophageal motility
In contrast to the lack of effect on the proximal peristalsis pattern, remifentanil exposure markedly altered the timing of distal peristalsis below the transition zone. Specifically, remifentanil caused distal peristalsis to become more rapidly propagated, hence reaching the EGJ earlier (shorter latency), while at the same time the distal contractile amplitude was unchanged. As distal smooth peristalsis is controlled via activation of the enteric nervous system, 24, 32, 33 we propose that our findings are consistent with peripheral MOR agonism causing an excitatory-inhibitory "imbalance" due to a selective reduction of nitric oxide (NO) release by inhibitory neurons. Such effects would be in keeping with the clinical observation of an increased incidence of spastic motor disorders of the distal esophagus in chronic opioid users, reported by Ratuapli et al. 7 Normally propagated primary peristalsis of the smooth muscle esophagus results from vagally mediated activation of nitrergic inhibitory neurons, followed by activation of cholinergic excitatory neurones. Along the esophageal body, the relative density of inhibitory innervation increases distally and so does the latency period from swallow to muscle contraction, producing the orderly and distally propagating peristaltic behavior that is typically seen in healthy subjects. 24 Via its effects on the CNS, remifentanil may in theory attenuate the vagal preganglionic nerve activation with the knock-on effect of altered postganglionic neurotransmitter release. However, as this effect would impact equally on both inhibitory and excitatory pathways, the overall timing of the distal peristalsis would not be expected to change, but perhaps rather its overall contractile amplitude be attenuated. We therefore propose that the main effects of MOR agonism are most likely via peripheral mechanisms, in particular reduced peripheral NO release by antagonising NO-synthase production. 33 Reduced peripheral NO release best explains our latency findings as they are akin to the effects of the NO synthase inhibitor nitro-Larginine methyl ester hydrochloride (L-NAME) which induces a similar rapid peristaltic sequence pattern in healthy volunteers. 34 An alternative peripheral mechanism may be remifentanil-induced disruption of sensory mechano-receptor-mediated peripheral circuits that modulate peristalsis in relation to luminal stimuli, most notably bolus-based distension. 35 While impairment of sensory modulation of peristalsis may in part explain the elevated distension pressures seen, it would also attenuate both inhibitory and excitatory pathways and therefore seems an unlikely mechanism governing the imbalance suggested by shorter distension-contraction latency. This is further supported by the observation that in the lower gut, opioids abolish, rather than modify, propagation of distension-induced peristalsis by completely interrupting neuroneuronal and neuroeffector transmission. 
| Remifentanil effects on lower esophageal sphincter and EGJ
Using manometry with circumferential or unidirectional pressure sensing, we can only assess the sum effect of MOR agonism on LES tone and relaxation, which is complete relaxation of a shorter duration. We lack the resolution to appreciate the radial asymmetry or assess striated and smooth muscle components separately.
Importantly bolus transit through the LES is not affected by remifentanil (Figures 1 and 2) , and the rapid propagation of the distal contraction continues to the LES and leads to increased intrabolus pressure above the LES. The bolus traverses the sphincter more rapidly due to the greater pressure differential between the distal esophagus and intragastric pressure. There are several potential explanations for the increased IRP4 seen in the majority of subjects in our study and previously observed during MOR agonist administration. 7 Firstly, in our study sphincter relaxation is of a shorter duration than the 4 seconds included in calculating IRP. Secondly increased intrabolus pressures will also increase IRP. Lastly, it is possible that remifentanil may have differential effects on striated and smooth muscle and/or the different smooth muscle components of the LES, or differential central and peripheral neural inhibition.
Nitric oxide is the main neural inhibitor involved in swallowinduced LES relaxation. 
| Limitations
We acknowledge that this study has some limitations. For example, the additional use of opioid receptor antagonism, such as naloxone, would have added to the findings in our study. Of note, previous stud-
ies have failed to demonstrate a reversal of the effects of remifentanil by either naloxone or methylnaltrexone; 1,7 however, a supratherapeutic dose of naloxone may be needed to reverse the effects of remifentanil. 44, 45 When considering remifentanil as a model for mu-opioid agonism, we acknowledge that the pharmacokinetics of remifentanil is markedly different from that of longer acting mu-opioids and thus any inference that longer acting mu-opioid agonists will have similar effects are only an assumption. Furthermore, we did not study the pharmacodynamics of remifentanil in our study. While we did not directly correlate impedance-based bolus flow in the esophagus or at the EGJ with simultaneous radiology, we note previous studies 46 validating nadir impedance as a marker of bolus distension and the bolus flow time to quantify the period of esophageal emptying. 19, 47 Swallowing maneuvers, including multiple rapid swallows, were not performed, but would have had utility in determining the level at which (whether centrally or peripherally) swallowing inhibition, leading to a shortened distal latency, originates. 33 Finally, we did not assess bolus volume effects or compare different bolus viscosities which may reveal altered sensory modulation of swallow features.
| CONCLUSION
In summary, we reported on remifentanil-induced changes in the proximal and distal esophagus, as well as at the EGJ. Proximally, there was a reduction in esophageal contractility and increased intrabolus pressures, a known correlate of bolus perception. 13 Distal changes in distension pressure and latency were in keeping with a reduction in descending deglutitive inhibition and, at the EGJ, there was a re- 
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